Plasma Angiotensin-Converting Enzyme in Alzheimer's Disease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The insertion allele in the gene encoding angiotensin-converting enzyme (ACE) is a risk factor for Alzheimer's disease (AD) and ACE is one of several peptidases that have the ability to degrade the neurotoxic amyloid-beta peptide. ACE is a membrane-bound peptidase that is also present in a soluble form in plasma as a result of a zinc metalloprotease-mediated shedding event. Here we aimed to determine whether there is a difference in ACE in the plasma of late-onset clinically diagnosed AD patients (n = 94) as compared to age-matched non-demented control subjects (n = 188). Plasma ACE was lower in the AD subjects as compared to the controls both at baseline (p = 0.072) and after two years (p = 0.05). There was a greater reduction in plasma ACE in the AD subjects as compared to the control subjects over the two years. Plasma ACE did not correlate with cognitive function. The observed reduction in plasma ACE in AD may reflect a general decrease in the zinc metalloprotease-mediated shedding of a subset of membrane-bound proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 2×
“Meta-analyses of the genetic data available to date have concluded that the I allele is associated with late-onset sporadic AD [13–15].”
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
Kehoe, P. G., Russ, C., McIlroy, S., Williams, H., Holmans, P., Holmes, C., Liolitsa, D., Vahidassr, D., Powell, J., McGleenon, B., et al. (1999) · Nature Genetics · doi:10.1038/5009 · Cited by 260 · cited 1×
“An association between the insertion (I)/deletion (D) polymorphism in intron 16 of the ACE gene and susceptibility to the development of AD was initially re-ported [12].”
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 1×
“In contrast, it has been reported that in mice deficient in ACE and in mice treated with ACE inhibitors, the steady state A β levels were no different to controls [19,20].”
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 1×
“Finally, follow-up of a group of individuals in the Cache County Study did not reveal ACE inhibitor use to have any effect on the incidence of AD, however, there was no distinction between those taking ACE inhibitors which cross the blood brain barrier or those without such capability [45].”
Cited by
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
(2009) · PubMed Central · Cited by 165
Xu, J., Begley, P., Church, S. J., Patassini, S., McHarg, S., Kureishy, N., Hollywood, K. A., Waldvogel, H. J., Liu, H., Zhang, S., et al. (2016) · Scientific Reports · doi:10.1038/srep27524 · Cited by 85
Self-citationA Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease
Belbin, O., Brown, K., Shi, H., Medway, C., Abraham, R., Passmore, P., Mann, D., Smith, A. D., Holmes, C., McGuinness, B., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101914 · Cited by 34
“Taken together with the observation that increased ACE levels and activity are observed in LOAD brains (reviewed in [5]) and are associated with increased plasma levels of A [6] and reduced levels of A in CSF [7, 8], these all point to the likely involvement of ACE in A -related pathology in AD.”
BackgroundWang, X.-B., Cui, N.-H., Yang, J., Qiu, X.-P., Gao, J.-J., Yang, N., & Zheng, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111406 · Cited by 15
“Manual search of references cited in the published articles revealed one additional article [38].”
Background
Metadata
- Authors
- Vardy, E. R. L. C., Rice, P. J., Bowie, P. C. W., Holmes, J. D., Catto, A. J., & Hooper, N. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2009-03-09
- Volume
- 16
- Issue
- 3
- Pages
- 609-618
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1530671051
- Cited by
- 32
- References
- 4
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma Angiotensin-Converting Enzyme in Alzheimer's Disease. https://app.cochat.ai/papers/10.3233/jad-2009-1002
- The paper
- Vardy, E. R. L. C., Rice, P. J., Bowie, P. C. W., Holmes, J. D., Catto, A. J., & Hooper, N. M. (2009). Plasma Angiotensin-Converting Enzyme in Alzheimer's Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2009-1002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.